Article Sidebar
Published:
Oct 15, 2022Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Clinical efficacy of the combined use of levofloxacin and different courses of isoniazid and rifampicin in the treatment of mild spinal tuberculosis
Abstract
Purpose: To investigate the clinical effectiveness of the combined use of levofloxacin and different courses of isoniazid and rifampicin in the treatment of mild spinal tuberculosis (TB).
Methods: The clinic data of 100 patients with light spinal TB were retrospectively reviewed. A double-blind technique was used to divide the patients into 6-month treatment group (M6 group, n = 32), 12-month treatment group (M12 group, n = 34) and 18-month treatment group (M18 group, n = 34). All patients were given isoniazid and rifampicin, in combination with levofloxacin. The effects of the different treatment courses on mild spinal TB were determined.
Results: There were significantly higher post-treatment levels of inflammatory factors in M6 group than in M12 and M18 groups (p < 0.001). Moreover, there were significantly higher Visual Analogue Scale (VAS) score and erythrocyte sedimentation rate (ESR), and larger focus size in M6 group than in M12 and M18 groups (p < 0.05). However, after treatment, M18 group had significantly higher total incidence of adverse reactions than M6 and M12 groups (p < 0.05).
Conclusion: Compared with the short-course treatment, long-course treatment with isoniazid and rifampicin in combination with levofloxacin is more effective in reducing the levels of inflammatory factors and decreasing focus size in patients with mild spinal TB. However, patients given the 18-month treatment tend to develop more adverse reactions. Therefore, 12-month treatment with the combined therapy is a better therapeutic option.
